- Home
- AUTL vs IMTX Comparison
AUTL vs IMTX Comparison
Compare AUTL & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- IMTX
- Stock Information
- Founded
- AUTL 2014
- IMTX N/A
- Country
- AUTL United Kingdom
- IMTX Germany
- Employees
- AUTL N/A
- IMTX N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AUTL Health Care
- IMTX Health Care
- Exchange
- AUTL Nasdaq
- IMTX Nasdaq
- Market Cap
- AUTL 625.4M
- IMTX 579.8M
- IPO Year
- AUTL 2018
- IMTX N/A
- Fundamental
- Price
- AUTL $2.31
- IMTX $5.59
- Analyst Decision
- AUTL Strong Buy
- IMTX Strong Buy
- Analyst Count
- AUTL 5
- IMTX 4
- Target Price
- AUTL $9.32
- IMTX $14.67
- AVG Volume (30 Days)
- AUTL 2.4M
- IMTX 864.1K
- Earning Date
- AUTL 08-07-2025
- IMTX 08-12-2025
- Dividend Yield
- AUTL N/A
- IMTX N/A
- EPS Growth
- AUTL N/A
- IMTX N/A
- EPS
- AUTL N/A
- IMTX N/A
- Revenue
- AUTL $9,011,000.00
- IMTX $155,801,989.00
- Revenue This Year
- AUTL $461.76
- IMTX N/A
- Revenue Next Year
- AUTL $112.66
- IMTX $1.92
- P/E Ratio
- AUTL N/A
- IMTX N/A
- Revenue Growth
- AUTL N/A
- IMTX 93.56
- 52 Week Low
- AUTL $1.11
- IMTX $3.30
- 52 Week High
- AUTL $5.00
- IMTX $13.09
- Technical
- Relative Strength Index (RSI)
- AUTL 69.32
- IMTX 51.19
- Support Level
- AUTL $1.98
- IMTX $5.29
- Resistance Level
- AUTL $2.10
- IMTX $5.60
- Average True Range (ATR)
- AUTL 0.13
- IMTX 0.33
- MACD
- AUTL -0.00
- IMTX -0.10
- Stochastic Oscillator
- AUTL 73.63
- IMTX 27.52
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.